Plant Medicine for Veterans: How Ibogaine, Psilocybin & MDMA Are Treating PTSD | Self Growth Videos

The US has approximately 400,000 veterans living with PTSD at any given time. The standard treatment — SSRIs, talk therapy, prolonged exposure — helps some of them. For a significant portion, nothing works. The VA’s own data shows that 20 veterans die by suicide every day in the United States.

That number hasn’t meaningfully moved in decades.

What has moved is the research. In the last five years, clinical results from ibogaine, psilocybin, and MDMA-assisted therapy for combat veterans have been remarkable enough that 60 Minutes ran a segment on it, the Department of Defense authorized funding, and members of Congress introduced legislation to expand access. This is no longer fringe. It is the most significant development in PTSD treatment in a generation.

Why Conventional Treatment Falls Short for Combat PTSD

Understanding why veterans respond so poorly to standard PTSD treatment requires understanding what combat trauma actually does to the brain.

PTSD isn’t just psychological distress. It’s a neurological restructuring. The amygdala — the brain’s threat-detection center — becomes hyperactivated, firing constantly even in safe environments. The prefrontal cortex, responsible for rational modulation of fear responses, becomes underactive. The hippocampus, which processes memory and context, is structurally altered. The result is a brain physically rewired around threat, unable to process or contextualize what happened.

SSRIs and conventional therapy work on the surface of this. They manage symptoms. What the plant medicines appear to do — and this is the key — is create a window of neuroplasticity in which the brain can actually rewire itself. Not managed. Resolved.

Ibogaine: The African Root That Resets the Brain

Ibogaine is derived from the iboga root, a plant native to the rainforests of Central Africa where it has been used for centuries in Bwiti initiation ceremonies. Pharmacologically, it acts on multiple receptor systems simultaneously — opioid, serotonin, NMDA — in a way that no synthetic drug replicates.

For veterans, two effects stand out.

First, ibogaine produces a sustained period of heightened neuroplasticity. In clinical and observational settings, veterans have described ibogaine as allowing them to revisit traumatic memories from a third-person perspective — observing what happened to them without being consumed by it. The emotional charge around the memory doesn’t disappear, but its grip loosens in a way that years of exposure therapy couldn’t achieve.

Second, ibogaine has shown dramatic results in opioid addiction — itself an enormous problem in the veteran population. A 2023 Stanford study of 30 special operations veterans treated at a clinic in Mexico (ibogaine remains Schedule I in the US) showed significant reductions in PTSD symptoms, depression, and anxiety that persisted at one-month follow-up. Disability ratings improved. Cognitive function improved.

One of the participants in that study was Dakota Meyer, a Medal of Honor recipient, who talked about his experience on the Joe Rogan Experience — the clip above. His account is worth watching in full.

Read more about ibogaine’s history and mechanisms in our complete ibogaine guide.

Psilocybin: The Johns Hopkins Data

The clinical results for psilocybin in PTSD and depression have been accumulating for over a decade, primarily from Johns Hopkins and NYU. The numbers are striking.

In one landmark Johns Hopkins study, two psilocybin sessions produced significant antidepressant effects in 71% of participants, with 54% in remission at one-month follow-up. For context: SSRIs typically show response rates around 40-50%, with much lower remission rates — and those participants are taking pills daily. Psilocybin participants took two doses total.

For veterans specifically, the PTSD mechanism is different from civilian depression but the neuroplasticity window appears similar. The current hypothesis is that psilocybin temporarily flattens the “default mode network” — the brain’s self-referential processing system. Hyperactive DMN activity is associated with rumination, depression, and the looping trauma recall that defines PTSD. Quieting it allows the brain to form new connections, integrate experiences, and stop replaying the same neural grooves.

The full breakdown of the psilocybin research is in our psilocybin therapy science page.

MDMA: The MAPS Data and the FDA Path

MDMA is not a classic psychedelic — it doesn’t produce visual hallucinations or ego dissolution. But in the context of trauma treatment, it may be the most precisely targeted of the three. MDMA massively increases oxytocin, reduces amygdala reactivity, and floods the brain with serotonin — creating a 4-6 hour window in which patients can discuss and process traumatic memories without the usual terror response.

The Multidisciplinary Association for Psychedelic Studies (MAPS) ran Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Results: 67% of participants no longer met PTSD diagnostic criteria after treatment. In the placebo group: 32%.

The FDA rejected full approval in 2024, citing concerns about blinding methodology — but the clinical results themselves were not disputed. The conversation about approval continues, and expanded access programs are operating in several states.

The Organizations Making This Happen

Several nonprofits are operating outside US law to get veterans into treatment:

VETS Solutions (Veterans Exploring Treatment Solutions) — founded by Marcus Capone, a former Navy SEAL. Has facilitated ibogaine and 5-MeO-DMT treatment for hundreds of veterans in Mexico. The Stanford study drew directly from their participant pool.

Heroic Hearts Project — connects veterans with ayahuasca and psilocybin retreats globally. Has facilitated over 1,000 veteran placements.

Zappy Zapolin — produced the documentary “The Last Shaman” and has been a public advocate for psychedelic treatment access for veterans specifically.

The Legislative Picture

The passage of the National Defense Authorization Act in 2024 included provisions authorizing DoD-funded clinical trials of psychedelic treatments for active duty military. Several states — Colorado, Oregon, and others — have created legal frameworks that veterans can access.

The bipartisan support is notable. This isn’t a left-right issue. Veterans with combat PTSD represent a population that crosses every political line, and the results are hard to dismiss on ideological grounds when the data is this clear.

What This Means for the Broader Conversation

The veteran PTSD story is doing something culturally important: it’s de-stigmatizing plant medicine for audiences who would never have engaged with it through the counterculture lens. When a Medal of Honor recipient describes ibogaine as the thing that finally freed him from his war, it lands differently than anything coming from traditional advocacy channels.

If you’re supporting a veteran dealing with PTSD — or if you’re a veteran yourself researching options — start with understanding the treatments:

• Ibogaine: The African Plant Medicine Transforming Addiction and PTSD
• Psilocybin Therapy: What the Research Actually Shows
• How to Choose a Plant Medicine Retreat
• Psychedelic Integration: What Happens After the Ceremony

Note: Ibogaine remains Schedule I in the United States. Most treatment is currently accessed in Mexico, where it is legal. Always research any program thoroughly before participating. See our retreat vetting guide for what to look for.